# Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

> **NCT00563927** · NA · UNKNOWN · sponsor: **Hospital Authority, Hong Kong** · enrollment: 340 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms
- Carcinoma, Squamous Cell

## Interventions

- **PROCEDURE:** Conventional RT
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT00563927
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** 2009-10
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2010-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563927, "Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00563927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*